These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 414285)

  • 21. Morphine dependence and self-stimulation: attenuation of withdrawal-induced weight loss.
    Glick SD; Marsanico RG; Zimmerberg B; Charap AD
    Res Commun Chem Pathol Pharmacol; 1973 May; 5(3):725-32. PubMed ID: 4735638
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of ondansetron administration on opioid withdrawal syndrome observed in rats.
    Pinelli A; Trivulzio S; Tomasoni L
    Eur J Pharmacol; 1997 Dec; 340(2-3):111-9. PubMed ID: 9537805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse.
    Bloom AS; Dewey WL
    Psychopharmacology (Berl); 1978 May; 57(3):243-8. PubMed ID: 97703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
    Yamaguchi T; Hagiwara Y; Tanaka H; Sugiura T; Waku K; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2001 Aug; 909(1-2):121-6. PubMed ID: 11478928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quasi morphine-abstinence syndrome.
    Collier HO; Francis DL; Henderson G; Schneider C
    Nature; 1974 May; 249(456):471-3. PubMed ID: 4545823
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute and subacute interactions between delta9-tetrahydrocannabinol and other drugs in the rat.
    Pryor GT; Husain S; Mitoma C
    Ann N Y Acad Sci; 1976; 281():171-89. PubMed ID: 1071364
    [No Abstract]   [Full Text] [Related]  

  • 27. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
    Dhawan K; Kumar S; Sharma A
    J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interference with withdrawal signs of naloxone-induced opiate withdrawal under anesthesia is anesthetic-specific in opiate-dependent rats.
    Streel E; Dan B; Bredas P; Clement B; Pelc I; Verbanck P
    Life Sci; 2001 Dec; 70(5):517-22. PubMed ID: 11811896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of administration of phentonium bromide on opioid withdrawal syndrome in rats.
    Pinelli A; Trivulzio S; Tomasoni L
    J Pharm Pharmacol; 1997 Dec; 49(12):1222-8. PubMed ID: 9466347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Withdrawal-like behaviour induced by inhibitors of biogenic amine reuptake in rats treated chronically with delta 9-tetrahydrocannabinol.
    Verberne AJ; Taylor DA; Fennessy MR
    Psychopharmacology (Berl); 1980; 68(3):261-7. PubMed ID: 6248916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma malondialdehyde levels and opiate withdrawal signs observed in rats treated with morphine plus naloxone: effects of alpha-lipoic acid administration.
    Pinelli A; Cighetti G; Trivulzio S
    Fundam Clin Pharmacol; 2008 Aug; 22(4):439-45. PubMed ID: 18705754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic delta9-tetrahydrocannabinol in rats: effect on social interactions, mouse killing, motor activity, consummatory behavior, and body temperature.
    Miczek KA
    Psychopharmacology (Berl); 1979 Jan; 60(2):137-46. PubMed ID: 106423
    [No Abstract]   [Full Text] [Related]  

  • 33. Cellular immune function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol.
    Bhargava HN; House RV; Thorat SN; Thomas PT
    Pharmacology; 1996 May; 52(5):271-82. PubMed ID: 8807671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A diminution of delta9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development.
    Mason DJ; Lowe J; Welch SP
    Eur J Pharmacol; 1999 Sep; 381(2-3):105-11. PubMed ID: 10554877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
    Tanda G; Loddo P; Di Chiara G
    Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marijuana: harder than thought?
    Wickelgren I
    Science; 1997 Jun; 276(5321):1967-8. PubMed ID: 9221496
    [No Abstract]   [Full Text] [Related]  

  • 37. Tolerance to delta9-tetrahydrocannabinol in adapted and nonadapted rabbits.
    Martin P; Consroe P
    Pharmacol Biochem Behav; 1978 Dec; 9(6):753-8. PubMed ID: 746051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electroencephalographic and behavioral tolerance to and cross-tolerance between D-Ala2-methionine-enkephalinamide and morphine in the rat.
    Tortella FC; Moreton JE; Khazan N
    J Pharmacol Exp Ther; 1979 Aug; 210(2):174-9. PubMed ID: 222892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of morphine tolerance and withdrawal on intestinal salt and water transport in the rat in vivo and in vitro.
    Warhurst G; Smith GS; Higgs N; Tonge A; Turnberg LA
    Gastroenterology; 1984 Nov; 87(5):1035-41. PubMed ID: 6541171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of GABA-induced abstinence behaviour in naive rats by morphine and bicuculline.
    de Boer T; Metselaar HJ; Bruinvels J
    Life Sci; 1977 Mar; 20(6):933-41. PubMed ID: 191711
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.